SOURCE: Bollinger Report

February 09, 2012 09:00 ET

A Forward Look, the Year Ahead - Featured Research on BioMarin Pharmaceutical Inc. and Amylin Pharmaceuticals, Inc.

HONG KONG--(Marketwire - Feb 9, 2012) - Today, introduced featured coverage of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). Full research reports are available to readers at:

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Bollinger Report screened and selected BioMarin Pharmaceutical Inc. for its current position within the healthcare industry. BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio consists of four approved products and multiple investigational product candidates. A copy of this report featuring BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is available at:

Bollinger Report is featuring Amylin Pharmaceuticals, Inc. for its changing role within the healthcare industry. Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Its wholly owned subsidiaries are Amylin Ohio, LLC, and Amylin Investments, LLC. To download researches and analysis on Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) we welcome investors to visit:

About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.

Contact Information